Communiqués Bioxytran, Inc.

Actions

BIXT

US09075D1028

Temps Différé OTC Markets Autres places de cotation 16:31:08 06/06/2024			Varia. 5j.	Varia. 1 janv.
0,12 ^USD	-1,23%		-3,85%	-20,00%

19/04	Bioxytran, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
19/04	Bioxytran, Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Bioxytran : Change in Certifying Accountants - Form 8-K	10/05	PU
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist	06/03	AQ
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19	21/02	AQ
Bioxytran Gets Broad Patent Coverage on 60+ Viruses	24/10/23	AQ
Bioxytran Interview at the Emerging Growth Conference	04/10/23	AQ
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M	14/09/23	AQ
Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients	07/09/23	AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	31/08/23	AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	24/08/23	AQ
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients	08/08/23	AQ
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board	31/07/23	AQ
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations	27/06/23	AQ
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment	12/06/23	AQ
Bioxytran Interview at the Emerging Growth Conference	01/05/23	AQ
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	19/04/23	AQ
Bioxytran Interview at the Emerging Growth Conference	03/04/23	AQ
BIOXYTRAN, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	31/03/23	AQ
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal	29/03/23	AQ
BIOXYTRAN, INC : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	07/03/23	AQ
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus	28/02/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bioxytran, Inc.

Actions

BIXT

US09075D1028

Communiqués

Filtres